A Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of UB-221 IV Infusion as an add-on Therapy in Patients With Chronic Spontaneous Urticaria (clinicaltrials.gov) - Oct 3, 2022 - P2 | N=25 | Not yet recruiting | Sponsor: United BioPharma | Trial completion date: Mar 2023 ➔ Dec 2023 | Initiation date: Jun 2022 ➔ Oct 2022 | Trial primary completion date: Mar 2023 ➔ Dec 2023
Trial completion date • Trial initiation date • Trial primary completion date • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria
|